• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Evolent Health Inc

    6/10/25 5:21:58 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary
    Get the next $EVH alert in real time by email
    S-8 1 d946530ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 10, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Evolent Health, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware  

    1812 North Moore Street, Suite 1705

    Arlington, VA 22209

      32-0454912

    (State or other jurisdiction of

    incorporation or organization)

     

    (Address of principal executive

    offices, including zip code)

     

    (I.R.S. Employer

    Identification No.)

    Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan

    (Full title of the plan)

    Jonathan Weinberg, Esq.

    General Counsel

    Evolent Health, Inc.

    1812 North Moore Street, Suite 1705

    Arlington, VA 22209

    (571) 389-6000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copy to:

    Elizabeth A. Morgan, Esq.

    King & Spalding LLP

    1185 Avenue of the Americas, 34th Floor

    New York, NY 10036

    (212) 556-2100

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY STATEMENT

    This Registration Statement is filed by Evolent Health, Inc. (the “Company”) pursuant to General Instruction E to Form S-8. The contents of the Registration Statements on Form S-8 previously filed on June  8, 2015 (File No. 333-204785), June 18, 2018 (File No. 333-225714), June 15, 2021 (File No. 333-257118) and November 3, 2023 (File No. 333-275287) are incorporated by reference herein and made a part hereof, except as supplemented, amended or superseded by the information set forth below. This Registration Statement on Form S-8 is filed by Evolent Health, Inc. to register an additional 7,126,000 shares of Class A common stock that may become issuable under the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan, as amended (the “Amended 2015 Plan”). The Amended 2015 Plan has been amended to (i) authorize an additional 7,126,000 shares of Class A common stock for issuance under the Amended 2015 Plan and (ii) authorize an additional 7,126,000 shares of Class A common stock that may be delivered pursuant to incentive stock options granted under the Amended 2015 Plan.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

     

    Exhibit

    Number

      

    Document Description

      5.1    Opinion of King & Spalding LLP with respect to the shares being registered.
     23.1    Consent of Deloitte & Touche LLP.
     24.1    Power of Attorney (included on the signature page hereto).
     99.1    Amendment to the Evolent Health Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan, filed as Appendix B to the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 25, 2025, and incorporated herein by reference.
    107    Calculation of Filing Fee Table.

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Arlington, State of Virginia, on June 10, 2025.

     

    EVOLENT HEALTH, INC.
    By:   /s/ Seth Blackley
      Seth Blackley
      Chief Executive Officer

    POWER OF ATTORNEY

    Each person whose signature appears below hereby constitutes and appoints John Johnson and Jonathan Weinberg and each of them singly, his or her true and lawful attorney-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated and on the 10th day of June 2025.

     

    Signature

      

    Title

     

    Date

    /s/ Seth Blackley

    Seth Blackley

      

    Chief Executive Officer and Director
    (Principal Executive Officer)

      June 10, 2025

    /s/ John Johnson

    John Johnson

      

    Chief Financial Officer

    (Principal Financial Officer)

      June 10, 2025

    /s/ Aammaad Shams

    Aammaad Shams

      

    Chief Accounting Officer and Controller

    (Principal Accounting Officer)

      June 10, 2025

    /s/ Toyin Ajayi, MD

    Toyin Ajayi, MD

      

    Director

      June 10, 2025

    /s/ Craig Barbarosh

    Craig Barbarosh

      

    Director

      June 10, 2025

    /s/ Russell Glass

    Russell Glass

      

    Director

      June 10, 2025

    /s/ Peter Grua

    Peter Grua

      

    Director

      June 10, 2025

    /s/ Shawn Guertin

    Shawn Guertin

      

    Director

      June 10, 2025

    /s/ Richard Jelinek

    Richard Jelinek

      

    Director

      June 10, 2025

    /s/ Kim Keck

    Kim Keck

      

    Director

      June 10, 2025

     

    2


    /s/ Cheryl Scott

    Cheryl Scott

      

    Director

      June 10, 2025

    /s/ Brendan Springstubb

    Brendan Springstubb

      

    Director

      June 10, 2025

     

    3

    Get the next $EVH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVH

    DatePrice TargetRatingAnalyst
    1/10/2025$15.00Buy
    Needham
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    4/22/2024$40.00Buy
    Citigroup
    3/1/2024$45.00Outperform
    Oppenheimer
    1/3/2024$39.00Overweight
    Barclays
    More analyst ratings

    $EVH
    SEC Filings

    See more
    • Evolent Health Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Evolent Health, Inc. (0001628908) (Filer)

      6/20/25 6:32:06 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • SEC Form S-8 filed by Evolent Health Inc

      S-8 - Evolent Health, Inc. (0001628908) (Filer)

      6/10/25 5:21:58 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Evolent Health Inc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Evolent Health, Inc. (0001628908) (Filer)

      6/5/25 4:55:52 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary